论文部分内容阅读
目的观察缬沙坦(商品名“怡方”)对轻、中度原发性高血压(essentialhypertension,EH)的降压疗效及其安全性。方法68例EH患者口服怡方80～160mg共6周,不服用其它降压药,观察血压、心率及各项实验室检查指标的改变。结果服药6周后血压为(138.0±21.8)/(90.0±13.5)mmHg,收缩压下降12.8mmHg,舒张压下降10.1mmHg。显效31例,有效32例,总有效率92.6%。有不良反应者7例。主要为头晕、乏力、头痛等,症状较轻,不需停药,治疗前后各项血液生化、肝肾功能无改变。结论新型长效血管紧张素II受体拮抗剂怡方对轻、中度EH患者具有降压作用,不良反应少,耐受性好。
Objective To observe the antihypertensive effect and safety of valsartan (brand name “Yifang”) on mild and moderate essential hypertension (Eh). Methods Sixty-eight patients with EH were enrolled in Yi-Fang 80 ~ 160mg for 6 weeks. Other antihypertensive drugs were not taken and the changes of blood pressure, heart rate and various laboratory tests were observed. Results After 6 weeks of treatment, the blood pressure was (138.0 ± 21.8) / (90.0 ± 13.5) mmHg, systolic blood pressure decreased 12.8mmHg and diastolic blood pressure decreased 10.1mmHg. 31 cases markedly effective, effective 32 cases, the total effective rate was 92.6%. There are 7 cases of adverse reactions. Mainly dizziness, fatigue, headache, mild symptoms, without stopping, before and after treatment of blood biochemistry, liver and kidney function without change. Conclusions Yi-Fang, a new long-acting angiotensin II receptor antagonist, has antihypertensive effect on patients with mild and moderate EH with few adverse reactions and good tolerability.